CGI Pharmaceuticals, Inc.

Cellular Genomics wins European patent for kinase technology

Cellular Genomics wins European patent for kinase technology

September 16, 2003

Branford, Conn.-based Cellular Genomics Inc. today announced that the European Patent Office has granted the company a patent that covers general methods for discovering enzyme inhibitors, as well as methods and compositions of a class of specific inhibitors of protein kinases, a major class of drug targets.
CGI was granted a U.S. patent for the same technology in May 2002.

Zalicus

CombinatoRx CEO named Innovator of the Year

CombinatoRx CEO named Innovator of the Year

September 25, 2003

Alexis Borisy honored by Technology Review, MIT's Magazine of Innovation, at the Emerging Technologies Conference

e-Dialog, Inc.

E-Dialog acquires Whitespeed's rich media e-mail division

E-Dialog acquires Whitespeed's rich media e-mail division

September 30, 2003

Adds top creative, technology capabilities from interactive shop

LEXINGTON, MA - September 30, 2003 - e-Dialog, the precision e-mail marketing innovator, has acquired the e-mail marketing business of top interactive agency Whitespeed, based in Santa Monica, CA. The acquisition consolidates e-DialogÕs role as a comprehensive provider of cutting-edge e-mail services, and includes Whitespeed's e-mail client relationships, creative rich media capabilities and staff.

AVEO Pharmaceuticals, Inc.

GenPath Pharmaceuticals Raises $42.7 Million In Series B Funding

GenPath Pharmaceuticals Raises $42.7 Million In Series B Funding

October 1, 2003

Cambridge, Mass. - October 1, 2003 - GenPath Pharmaceuticals, Inc., a drug discovery and development company focused on the treatment of cancer and other diseases, announced today that it has raised $42.7 million in a Series B financing.

CGI Pharmaceuticals, Inc.

Cellular Genomics and Affymetrix form research collaboration to develop novel high-content drug screens

Cellular Genomics and Affymetrix form research collaboration to develop novel high-content drug screens

October 9, 2003

Branford, Conn. - October 9, 2003 - Cellular Genomics, Inc. (CGI), a chemical genetics based biopharmaceutical company, today announced that it has established a research collaboration with Affymetrix, Inc. the pioneer in creating breakthrough tools that are driving the genetic revolution. In the collaboration, CGI will use Affymetrix GeneChip(R) brand technology in conjunction with CGI's chemical genetics Analog Sensitive Kinase Allele (ASKA) technology for the development of unique high-content assays for kinase drug discovery.

Morphotek, Inc.

Morphotek announces contract manufacturing and development collaboration agreement with Baxter Healthcare Corporation

Morphotek announces contract manufacturing and development collaboration agreement with Baxter Healthcare Corporation

October 20, 2003

Exton, PA - October 20, 2003 - Morphotek Inc announced today that it has signed a Contract Manufacturing and Development Collaboration Agreement for use of its proprietary MORPHODOMA® technology for the development of high-titer cell lines for the manufacture of monoclonal antibody products and other biologics.

Flagship Ventures names former president of Wyeth Research, L. Patrick Gage, Venture Partner

Flagship Ventures names former president of Wyeth Research, L. Patrick Gage, Venture Partner

October 23, 2003

Pharmaceutical executive to focus on biopharmaceutical innovators

Selventa

Genstruct Appoints Sharan A. Pagano Vice President, Business Development & Alliances

Genstruct Appoints Sharan A. Pagano Vice President, Business Development & Alliances

October 29, 2003

Former Incyte, Proteome Executive Joins Mechanism Discovery Company

Wednesday October 29, 9:00 am ET CAMBRIDGE MA - Genstruct Inc., a biotechnology company that develops conceptual biological models to determine compound mechanisms of action and identify biomarkers for drug discovery and development, today announced the appointment of Sharan A. Pagano as Vice President, Business Development & Alliances.

AVEO Pharmaceuticals, Inc.

GenPath Pharmaceuticals and Merck enter into potential $100 million deal for the discovery of novel cancer drugs

GenPath Pharmaceuticals and Merck enter into potential $100 million deal for the discovery of novel cancer drugs

November 17, 2003

CAMBRIDGE, Mass. - November 17, 2003 - GenPath Pharmaceuticals, Inc., a drug discovery and development company focused on the treatment of cancer and other diseases, announced today that it has entered into a multi-year collaborative agreement with Merck & Co., Inc. (NYSE: MRK). Under the agreement, GenPath will use its proprietary cancer models to identify essential tumor maintenance genes which maybe suitable targets for the development of small molecule oncology agents. GenPath will also use its inducible, spontaneous tumor models to guide candidate drug selection and optimization.

Morphotek, Inc.

Morphotek announces issuance of broad patent covering the generation of optimized yeast strains for biotherapeutic and biological product discovery, development, and manufacturing

Morphotek announces issuance of broad patent covering the generation of optimized yeast strains for biotherapeutic and biological product discovery, development, and manufacturing

December 15, 2003

Exton, PA, December 15, 2003 -- Morphotek Inc. announced today that the United States Patent and Trademark Office has issued it U.S. Patent 6,656,736 covering the generation of novel, genetically evolved yeast strains for use in biotherapeutic and biological product discovery, development, and manufacturing.